NCT06908707View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

October 23, 2025

Study Completion Date

October 23, 2025

Conditions
PostmenopausalHealthy Adult Female Participants
Interventions
DRUG

LAE102 SC

A single dose of LAE102 will be administered subcutaneously

DRUG

Placebo SC

A single dose of placebo administered subcutaneously

DRUG

LAE102 IV

A single dose of LAE102 administered intravenously

DRUG

Placebo IV

A single dose of placebo administered intravenously

Trial Locations (1)

32117

Fortrea Clinical Trials, Daytona Beach

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Laekna Limited

INDUSTRY

NCT06908707 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women | Biotech Hunter | Biotech Hunter